Portugal – Antineoplastic and immunomodulating agents – 2023/0491-PERTUZUMAB +TRASTUZUMAB [80 + 40 MG/ML; SOL INJ; FRS]

Unlock Full Tender Insight

Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.

It's free to get started. No credit card required.